Research Article
Class 3 Obesity in a Multidisciplinary Metabolic Weight Management Program: The Effect of Preexisting Type 2 Diabetes on 6-Month Weight Loss
Table 2
Glycaemic control and diabetes medications at 6 months, for patients who had T2DM at baseline.
| | Variable ( or %) | Baseline () | 6 months () | value |
| | HbA1c () | | HbA1c (%) | | | 0.003 | | HbA1c (mmol/mol) | | | | | Percentage with | 19.7 | 31.6 | 0.035 | | Number of diabetes medications per patient | | | <0.001 | | Type of therapy (%) | | Lifestyle only | 8.4 | 50.6 | <0.001 | | Monotherapy | 30.1 | 19.3 | 0.18 | | ≥2 medications | 61.4 | 30.1 | <0.001 | | Type of medication (%) | | Metformin | 79.5 | 43.4 | <0.001 | | Sulphonylurea | 18.1 | 6.0 | 0.03 | | DPP-4 inhibitors | 14.5 | 7.2 | 0.18 | | GLP-1 analogues | 10.8 | 7.2 | 0.61 | | SGLT-2 inhibitors | 26.5 | 14.5 | 0.087 | | Acarbose | 1.0 | 0.0 | N/A | | Insulin | 33.7 | 20.5 | 0.061 | | Insulin total daily dose (units) | | | 0.014 | | Prescribing pattern (%) | | Weight-neutral/losing | 43.4 | 24.1 | 0.024 | | Weight-gaining | 34.9 | 21.7 | 0.071 | | Mixed-effect | 13.3 | 3.6 | 0.057 |
|
|
